SCHEMBL20583639

SCHEMBL20583639

CC[Si](CC)(CC)OCC(C)CC(=O)Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.43
▸ ABCC4 O15439 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MMP12 P39900 2/20 0.39
▸ HRH3 Q9Y5N1 2/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ FAAH O00519 1/20 0.38
▸ MEN1 O00255 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20583638 1.00 GAA (0.43) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572803 0.87 GAA (0.45) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572794 0.83 GAA (0.46) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572806 0.82 GAA (0.41) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572795 0.82 GAA (0.49) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572788 0.81 TSHR (0.47) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572810 0.79 GAA (0.45) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572801 0.79 LMNA (0.45) GAAABCC4LMNATSHRPTGS1
SCHEMBL21572797 0.78 LMNA (0.53) GAAABCC4LMNATSHRPTGS1
SCHEMBL20583245 0.77 GAA (0.43) GAAABCC4LMNATSHRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370739-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-06-28 — — US disclosed
EP-3424899-B1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2022-05-11 — — EP disclosed
CN-106977415-B Intermediate of shakubiqu and preparation method thereof 广东东阳光药业有限公司 2021-03-26 — — CN disclosed
US-20200079721-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) 2020-03-12 — — US disclosed
US-10479753-B2 Sacubitril intermediate and preparation method thereof SUNSHINE LAKE PHARMA CO., LTD (CN) 2019-11-19 — — US disclosed
EP-3424899-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2019-01-09 — — EP disclosed
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079721-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF DPP4, ACE, DPP8 GAA 63/4885ABCC4 3539/4885LMNA 1222/4885
US-20180362439-A1 SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF ACE, DPP4, SI GAA 63/4885ABCC4 3613/4885LMNA 2313/4885
US-11370739-B2 Sacubitril intermediate and preparation method thereof DPP4, ACE, DPP8 GAA 63/4885ABCC4 3539/4885LMNA 1222/4885
US-10479753-B2 Sacubitril intermediate and preparation method thereof ACE, DPP4, SI GAA 63/4885ABCC4 3613/4885LMNA 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback